Ciardullo, Stefano http://orcid.org/0000-0003-2422-3041
Morieri, Mario Luca
Daniele, Giuseppe
Fiorentino, Teresa Vanessa
Mezza, Teresa
Tricò, Domenico
Consoli, Agostino
Del Prato, Stefano
Giorgino, Francesco
Piro, Salvatore
Solini, Anna
Avogaro, Angelo
Funding for this research was provided by:
Università degli Studi di Milano - Bicocca
Article History
Received: 13 February 2024
Accepted: 4 May 2024
First Online: 3 June 2024
Declarations
:
: SC received lecture or consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novo Nordisk; MLM received lecture or consultancy fees from Amarin, Amgen, AstraZeneca, Eli Lilly, MSD, Novo Nordisk, SlaPharma, and Servier; DT received lecture or consultancy fees from Amarin, AstraZeneca, Eli Lilly, and Novo Nordisk. SDP has received research funding from AstraZeneca, Boehringer Ingelheim, Novartis Pharmaceuticals Co., and Merck Sharpe & Dohme, and is a consultant for or has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Janssen Pharmaceuticals, Laboratoires Servier, Merck Sharp & Dohme, Novartis Pharmaceuticals Co., Novo Nordisk, Sanofi, and Takeda. AC has received consulting or speaker fees from Bristol Meyer Squibb, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo-Nordisk, Sanofi-Aventis, Sigma-Tau, Takeda. FG reports consultancies or paid advisory board memberships for Eli Lilly, Medtronic, Novo Nordisk, Roche Diabetes Care, and Sanofi; grants received from Eli Lilly, Lifescan, and Roche Diabetes Care; lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diabetes Care, and Sanofi; and patents pending from Roche Diabetes Care. AS reports consultant fees from, Bayer, Eli Lilly Novo Nordisk and Sankyo, and lecture fees from Bayer, Eli Lilly, Novo Nordisk, and Sanofi-Aventis. AA received research grants and lecture or advisory board fees from MSD, AstraZeneca, Novartis, Boehringer Ingelheim, Sanofi, Mediolanum, Janssen, Novo Nordisk, Lilly, Servier and Takeda. No other potential conflicts of interest relevant to this article were reported.